Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06970457 · ClinicalTrials.gov registry record · NA

The Interaction of Body Composition, Sex Hormones and Exercise in Men

A NA study of Normal-weight Obesity, sponsored by Oklahoma State University.

Recruiting
Registry status
NA
Development phase
96
Enrollment target
1
Study location

NCT06970457: Recruiting NA study of Normal-weight Obesity, sponsored by Oklahoma State University.

NCT06970457 is a NA study of Normal-weight Obesity that is actively recruiting participants, run by Oklahoma State University. The registered enrollment target is 96 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06970457, a NA study of Normal-weight Obesity, is actively recruiting participants, sponsored by Oklahoma State University.

RECRUITING
Registry status
NA
Development phase
96 participants
Enrollment target
1
Study location

Study Summary

The overall objective of this project is to advance understanding of the causes of normal weight obesity (NWO) in men, namely the hormone profile and related potential mediating mechanisms, and the efficacy of different modes of exercise to restore body composition and cardiometabolic health in this population.

Primary Outcome

Fat mass, measured in kg and as a percentage of total body mass Measured through dual-energy X ray absorptiometry

Conditions Studied

Interventions

  • BEHAVIORAL Aerobic Exercise Training
  • BEHAVIORAL Resistance Exercise Training

Study Locations (1)

Oklahoma

  • Oklahoma State University - Stillwater

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2025-04-15
Est. Completion 2026-12-31
Phase NA
Oklahoma State University

26 total trials

What NCT06970457 shows while recruiting

NCT06970457 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Normal-weight Obesity appearing as the primary indexed condition, and to 2 interventions - of which Aerobic Exercise Training is the first listed.

NCT06970457 reports a single indexed study location in Oklahoma.

Frequently Asked Questions

What is clinical trial NCT06970457 about?

NCT06970457 is a clinical study titled "The Interaction of Body Composition, Sex Hormones and Exercise in Men". The overall objective of this project is to advance understanding of the causes of normal weight obesity (NWO) in men, namely the hormone profile and related potential mediating mechanisms, and the efficacy of different modes of exercise to restore body composition and cardiometabolic health in this...

What is the current status of trial NCT06970457?

This trial is currently recruiting. It is a NA study. The enrollment target is 96 participants. The study started on 2025-04-15. Estimated completion is 2026-12-31.

What conditions does trial NCT06970457 study?

This clinical trial studies the following conditions: Normal-weight Obesity.

What interventions are being tested in trial NCT06970457?

The interventions under investigation include: Aerobic Exercise Training (BEHAVIORAL), Resistance Exercise Training (BEHAVIORAL).

Who is sponsoring clinical trial NCT06970457?

This trial is sponsored by Oklahoma State University, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06970457 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Normal-weight Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06970457's enrollment target sits among peer trials

96 926th of 2000 higher than 1,070 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03401762 · 96 participants · NA

    Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

  • NCT03471260 · 96 participants · Phase 1

    Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • NCT03549559 · 96 participants · NA

    Imaging Histone Deacetylase in the Heart

  • NCT03841058 · 96 participants · Phase 2

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06970457, the US trial registry maintained by the National Library of Medicine. NCT06970457 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.